Good afternoon. Thank you for joining us today to discuss LifeMD’s Fourth Quarter and Full-Year 2020 Results ended December 31, 2020. Joining us today is the Chief Executive Officer of LifeMD, Justin Schreiber; and the Company's Chief Financial Officer, Marc Benathen. Following their remarks, we'll open the call to your questions. Before we conclude today's call, I'll provide some important cautions regarding the forward-looking statements made by management during the call. I'd like to remind everyone that today's call is being recorded and will be made available for the telecom replay via instructions in today's press release which is available in the Investor Relations section of the company's website. And now I'd like to turn the call over to LifeMD’s CEO, Justin Schreiber. Please go ahead.

Thank you, Christy and good afternoon, everyone. Thanks for joining us today. 2020 was an incredible year for telemedicine and a stellar year for LifeMD. Our top line grew by nearly 200% to a record $37.3 million, adding back $917,000 in deferred revenue we lost due to our record level of subscriptions. Adjusted sales totaled $38.2 million for the year. And we ended 2020 exceptionally strong with December revenues hitting a monthly record of $5.2 million, up 316% over December of the previous year. In fact, December 2020 alone eclipsed the entire fourth quarter of 2019. 2020 was also a year of unprecedented change caused by the pandemic. Despite the challenges and heartbreaks, perhaps one silver lining to the pandemic is how it catalyzed the rapid expansion and evolution of the telehealth industry for the benefit and well-being of consumers. And we have evolved and expanded along with it from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth products and services. Our recent name change from Conversion Labs to LifeMD reflects this evolution. Ever since we embarked upon this journey two years ago, our vision has always been to radically change healthcare by making access to the best physician's diagnosis and treatment easily accessible, convenient, and affordable. From discreetly treating men's sexual health and women's hair loss to the upcoming rollout of our new teledermatology and concierge telehealth services, LifeMD is now at the forefront of a telehealth revolution, improving healthcare for countless Americans. Now, with the first quarter of 2021 nearly closed, we continue to expect more than $70 million in revenue for the quarter, which would be up more than 30% sequentially and up 295% compared to the same year-ago quarter. All this growth reflects the huge investments we made in the second half of last year, and especially in the fourth quarter to scale our platform and capture new customers and market share. This has driven record levels of new subscribers and net orders in our telemedicine business. In fact, our subscription rate for new telemedicine orders has grown from 20% early last year to now more than 91%, and we believe that new subscribers are worth far more than the investment we made to acquire them. This also means that our traditionally reported annual recurring revenue from subscriptions is now nearly the same as our top-line annual run rate, with our top line run rate currently exceeding $75 million based on March estimated results. As remarkable as this growth and market expansion has been, we believe we've only begun to scratch the surface of what we see as a $600 billion and growing addressable market opportunity. And to capture more of this fast-growing market, we’re planning to launch additional telehealth products and services throughout the year that we expect will further strengthen our high growth outlook. But before getting more into these new offerings in our outlook for 2021, I'd like to turn the call over to our CFO, Marc Benathen, who will take us through the financial details for the quarter and the year. I'm going to deviate from the script for a moment to formally welcome Marc for our first earnings call. We talked a lot about the amazing marketing and operations team that we have at LifeMD which we believe is one of our main competitive advantages. However, having Marc on board as our CFO is truly game-changing for the company and our shareholders. And I'm extremely confident that the expertise and experience Marc brings to the table will allow LifeMD to achieve a lot more than we otherwise would have, if we didn't have him on the team. So welcome aboard Marc and go ahead.

Thank you, Justin, and good afternoon, everyone. It has been about a month since I joined LifeMD, and I could not be more impressed by the energy and passion of the entire team. And this has been evident in the phenomenal growth the company has been driving over the past year. Like Justin, I truly believe we have only begun to scratch the surface of LifeMD’s long-term potential. As Justin mentioned, 2020 was a record year marked by substantial growth across all of our products and services. Revenue in the fourth quarter of 2020 totaled a record $12.9 million, up 227% on the fourth quarter of 2019. The growth was primarily driven by a 293% increase in telehealth net revenues to $10.3 million. Our PDFSimpli subsidiary contributed net revenue of $2.6 million, up 96% from the year-ago quarter. Including $917,000 at year-end deferred revenue associated with recurring subscriptions, total adjusted revenue on a non-GAAP basis would have been $13.8 million for the fourth quarter of 2020. Annual recurring revenue or ARR from subscriptions at December 31, 2020, reached a record $53.3 million, up 443% compared to the end of 2019. As of today, we estimate our ARR from subscriptions has increased to $75.9 million, up 267% year-over-year. We calculate ARR from subscriptions by multiplying by 12, the monthly sum of revenue attributed exclusively to subscription sales. We don't consider a single sale to customers that purchase products through the company's regular checkout pages, third-party online marketplaces, or involving the assistance of a customer service representative. Beginning with the reporting of these fourth quarter and full-year 2020 results, this calculation includes revenue from the initial purchase of patients who signed up under a recurring subscription plan. We believe this more accurately represents the current annualized value of our subscription customers. For future reporting periods, we’re evaluating and looking at introducing additional alternative metrics for tracking performance. Gross profit in the fourth quarter increased 184% to $8.9 million, compared to $3.1 million in the same year-ago quarter. Gross profit as a percentage of revenue in the fourth quarter of 2020 decreased to 59.1% from 79.6% in the same year-ago quarter. However, the decrease was primarily due to a change in the mix of product sales and inventory write-offs associated with legacy products. Excluding the impact of these non-cash write-offs, the adjusted gross margin on a non-GAAP basis for the fourth quarter of 2020 would have been 76.1%. Operating expenses in the fourth quarter of 2020 were $41.2 million, up from $3.7 million in the same year-ago quarter. The increase was primarily due to increases in selling and marketing expenses of $15.2 million, as well as general and administrative expenses of $21.7 million, other operating expenses of $479,000, customer services expenses of $66,000, and development costs of $93,000. The increase in general and administrative expenses was primarily due to $20.1 million in non-cash stock-based compensation and amortization. The majority of the stock-based compensation was related to performance targets achieved during the quarter that had been granted to the founders of the company in prior years. The non-cash cost basis of these awards was set at the price of the company shares at the time of their issuance, which had hit record levels during the fourth quarter. This substantial increase in expenses also reflects our strategic acceleration of investment in patient acquisition and extending market share as consumers sought out their telemedicine options in record numbers during the period. The result of this investment has positioned us very well for elevated growth in 2021 and beyond, due to a nearly 200% increase in new patients in the fourth quarter alone, with about 90% of these new patients signing up for recurring subscription plans. As Justin mentioned, our subscription rates for new telemedicine orders have increased from 20% early last year to currently more than 91%. And based on our analysis, the substantial investments we have made to acquire these committed subscribers have demonstrated a high return on investment. Our GAAP net loss attributable to common stockholders for the fourth quarter totaled $32.3 million or $2.56 per share. This compares to a net loss attributable to common stockholders of $712,000 or $0.09 per share in the fourth quarter of 2019. In addition to the stock-based compensation, our net loss for the fourth quarter of 2020 included other substantial non-cash or financing-related charges, such as interest expense of $355,000, combined amortization expenses of $48,000, non-cash expenses associated with legacy warrant settlements of $914,000, non-cash inventory write-off for legacy products of $903,000, accrued interest of $90,000, and financing transaction expenses of $175,000. Adjusted EBITDA, a non-GAAP term which factors out these items, totaled a loss of $9.7 million in the fourth quarter of 2020. This compares to adjusted EBITDA of $492,000 in the same year-ago quarter. Now turning to the full-year 2020. Revenue for the full-year increased 199% to a record $37.3 million, up from $12.5 million in 2019. The increase in revenue was attributable to both the increase in telehealth net revenues of 208% to $30.6 million and an increase in PDFSimpli net sales of 165% to $6.7 million. Including $917,000 year-end deferred revenue associated with recurring subscriptions, total adjusted revenue on a non-GAAP basis was $38.2 million for the full-year. Gross profit increased 185% to $28.4 million with gross profit as a percentage of revenue decreasing to 76.1% from 79.7% in 2019. The decrease was primarily due to inventory adjustments associated with legacy products as well as due to the mix of products sold. Excluding the non-cash inventory adjustments of $2.1 million, adjusted gross profit on a non-GAAP basis for the full-year of 2020 was $30.5 million or 81.8% as a percentage of revenue. Our operating expense for the full-year 2020 totaled $86.2 million, which was up from $12.8 million in 2019. The increase was primarily due to increases in selling and marketing expenses of $32.8 million, as well as general and administrative expenses of $39.8 million, other expenses of $442,000, customer service expenses of $146,000, and development costs of $224,000. General and administrative expenses for the full-year also included non-cash stock-based compensation of $37 million. Likewise, our expense increased in the fourth quarter and for the year reflects our strategic acceleration of investment in patient acquisition and securing market share as consumers sought out their telemedicine options in record numbers during the year. Our GAAP net loss attributable to common stockholders for the full-year of 2020 was $63.4 million or $4.44 per share, as compared to a net loss attributable to common stockholders of $3.1 million or $0.32 per share. The net loss for the full-year of 2020 included certain non-cash or financing-related charges such as interest expense and accrued interest of $514,000, amortization expense of $1.2 million, warrant settlements of $914,000, financing transactions of $237,000, acceleration of debt discount of $500,000, inventory adjustments that were non-cash of $2.1 million, non-cash deemed distributions of $4.7 million, and stock-based compensation expense of $37 million. Adjusted EBITDA, which factors out these items, totaled a loss of $16.3 million in the full-year of 2020 compared to a loss of $685,000 in 2019. Now turning to our balance sheet. Cash totaled $9.2 million at December 31, 2020, as compared to $917,000 at September 30, 2020. The increase was primarily due to a private placement with net proceeds of $14.9 million completed in November 2020. We believe our current cash position and available funds provide the company with ample liquidity to meet our current needs and plans for growth. In the coming quarter or two, we’re planning to enhance our liquidity significantly through non-dilutive means and we are actively engaged in this endeavor. We believe greater liquidity will enable us to further accelerate our growth and expand our market share at this pivotal time with the rapid growth and expansion of the telemedicine industry at unprecedented levels which wraps up our financial results.

Thanks, Marc. Clearly, the growth we've been experiencing over this past year has been incredible. We nearly tripled our top line in 2020. And now just three months into the New Year, we're hitting an annualized revenue run rate of more than $75 million. Our growing recurring revenue streams in subscriptions now represent about 91% of our total revenue given that nearly all of our customers are now on a subscription product either monthly or quarterly, we have much greater visibility into our revenue and future growth rates. We’re seeing 2021 already on track to be another record setting year, even if we fully discount the contribution for new products and brand launches during the year. Our increasing momentum throughout 2020 and into the New Year reflects how our telehealth platform has been able to provide accessible healthcare to a rapidly growing number of patients across the country. To-date between just our Rex MD and Shapiro MD brands that treat over 300,000 patients and customers nationwide. Given the many major milestones we achieved in 2020, we now have a foundation for continued strong growth with a differentiated telehealth business model that offers patients convenient and affordable access to health care services, low prescription and over-the-counter medications. One of these major milestones in 2020 was the official launch of our LifeMD Digital Telehealth platform that represents the culmination of years of development by experts in technology, medicine, and regulatory affairs. Owning our own robust and flexible end-to-end telehealth platform allows us to offer highly customized and targeted telemedicine offerings, which results in better patient care and high levels of satisfaction among our patients. It also gives us the ability to quickly test, launch and scale new telemedicine offerings. Such offerings include our new teledermatology brand and clinic for women, Nava MD, which we're planning to launch in the coming week. Nava MD will initially offer virtual treatment for many common dermatological conditions such as acne, rosacea, hyperpigmentation, and signs of aging. In addition to prescription products, we find a key exclusive licensing agreement in 2020 with Restorsea, a leading medical-grade skincare technology platform. It includes patented medical grade over-the-counter products for treating these prevalent skin conditions, integrating Restorsea’s clinically proven technology into our Nava MD offerings represents a major competitive advantage for us as we enter this high growth market segment. We have also been finalizing the rollout plan and technology infrastructure for our subscription-based primary care and concierge telehealth services, which will be offered under the LifeMD brand. We believe LifeMD’s concierge care offering will revolutionize the way our patients access the healthcare provider, enhance their healthcare experience, and dramatically strengthen our ability to positively impact their long-term health. The platform will combine a low-cost prescription drug offering, discounted access to all of our cascade telemedicine offerings, and on-demand access to the same doctor. While the offering will initially be launched in the U.S., we believe it has global appeal given the high regard for U.S. medical professionals and treatment in international markets. While the rapid emergence of telemedicine reflects a major shift in patient preference for virtual care, it has also begun to disrupt the traditional healthcare commercialization model; pharmaceutical and medical device diagnostic companies will have to adjust their commercial models accordingly. We see this opening up new direct-to-consumer joint venture and partnership opportunities for LifeMD and further enhancing our value proposition. These are clearly unprecedented times for the healthcare and telemedicine industry. The state of the telemedicine industry today is reminiscent of the beginning of the e-commerce era. There were many winners and losers, but the biggest winners were those who made the biggest timely investments in customer acquisition, customer care, and market share like Amazon and eBay. We’re at a similar stage with virtual healthcare and telemedicine; the industry is still very much in its nascent stage, we have the opportunity to become the 800-pound gorilla in the space like Amazon is to e-commerce and eBay to online auctions, and this is our vision. We recognize that the future of our company and our fulfillment of this vision will be determined by how our patients and customers experience our telehealth brands and services and how loyal they'll become to our offerings as a result. So we have and will continue to invest heavily in recruiting, training, and deploying the best people and professionals across our physician network, clinical support team, and customer service center. We’ll also continue to deploy the strongest marketing campaigns to capture new subscribers and market share. A $14 million strategic private placement we completed in February supports our aggressive growth initiatives for 2021, including further scaling the size and reach of our digital health ecosystem, launching our concierge telehealth service, expanding our suite of brands for men's and women's health, and accelerating overall customer acquisition. We’re preparing to launch treatments for new indications under our existing popular telehealth brands Rex MD and Shapiro MD; they have been carefully designed to serve the evolving needs of our patients, especially to attract new patients to our platform. We’re now at a stage where we have strong cash flow being generated by a large subscriber base, and besides our expense, our new customer acquisition, which has a strong ROI. We run a pretty tight ship, so we believe we're now in a strong position to secure additional growth capital as needed through non-dilutive or mostly non-dilutive means as Marc mentioned earlier in the call. Given our visibility into future performance provided by our high level of subscription revenue for the full-year 2021, we’re forecasting revenue in the range of $85 million to $95 million, which will represent an increase of 128% to 155% over 2020. Looking ahead, we're confident more than ever that our LifeMD telemedicine platform will continue to drive tremendous growth and opportunity, and especially greater shareholder value over the months and years to come. Now with that, we’d like to open the call to your questions. Christy?

And first we’ll go to David Larsen from BTIG. Your line is open.

Can you talk a little bit more about the subscription component of the business? Obviously, the revenue coming from subscription services has increased significantly as a percentage of total, just how exactly does that work please and what's actually included in that subscription? Like is it $200 a month, is it $200 a year, and what are customers actually getting with that? Thanks.

Thanks David, Marc can you take that?

Yes, so most of the subscription revenue, and all of it in the telehealth business today, is product-driven. So what the customer gathers on the prescription side say on Rex or on the OTC or prescription side on Shapiro, they get the products that they need for their given diagnosis. They will get that subscription every box shipped to their door, and we charge them on a recurring basis. Alternatively, we also do offer three-month subscription options where you will get a three-month supply and then it will get billed every three months. But it's truly recurring revenue in nature where we bill a customer on a recurring basis every month auto ship, auto charge.

Okay, great. So it's a subscription to the product over the course of say a year for example, and the members charge on a consistent and regular basis and ship to them like every quarter, every month?

David, this is Justin. It's essentially the patient or the customer is either paying a monthly or quarterly fee, which is all inclusive of the treatment that our physicians provide right and the product, whether it be prescription or OTC that the patient or customer is receiving from us.

Okay, great. Thanks. And then can you maybe talk a little bit more about the incremental service lines that are going to be developed and deployed over the upcoming months like dermatology, mental health, cholesterol? Which ones do you think can drive the most revenue for you, and which ones are you most excited about?

Yes, David. The two that we're really excited about, first of all, we've launched in the last couple of weeks compounded topical drug offering prescribed by a physician, which was sold in combination given to patients in combination with our patented shampoo conditioner products for hair loss. The initial data from that is very, very strong, I mean even stronger than when we initially launched our first Rex offers. So we're very encouraged about that; we think that there's a very big opportunity in female hair loss, it's very difficult for women to get to a dermatologist for treatment indications, and so we're very optimistic about that offering this year. Then we're launching this week, actually, we're going to soft launch our Nava MD dermatology offerings, which again we don't have data on because we haven't launched that, but we've closely followed some of our peers with very similar products. So I mean we believe that that's going to be a meaningful contributor to growth this year as well. And then look for competitive reasons, I'd rather not speak specifically on other indications that we plan to launch this year, but I'll just say generically that we're looking at several other markets that we think are a perfect fit for direct-to-consumer telemedicine. The total addressable market is massive, even bigger than erectile dysfunction and hair loss, and we're very, very excited to prove out another one or two indications this year in massive markets. So more to come on some other areas, David.

Okay, and then just one more for me. Can you talk a little bit about your primary care and concierge solution that you're going to be bringing to market? Any more detail around that would be very helpful. I think I heard in your prepared comments you said that members and patients will have sort of immediate access or direct access to the same physician on a sort of consistent basis. Just will those, any more color around that would be helpful like will you be employing those doctors, will those come from a sort of rented network initially, or like a monthly fee will be for those patients, it would be very helpful? And then also if those members need a referral into an acute care system, do you have any sort of longer-term plans for developing those types of provider networks? Thank you.

So to start to provide a little more detail on the LifeMD offering, LifeMD is going to be a cash pay subscription-based concierge care offering. We anticipate the range of price from $50 to $150 a month for more integrative care or providers that specialize in integrative medicine. We see LifeMD as being an incredible thing for our patients long-term; that was the genesis of the concept. It was like what we're bringing in large numbers of patients for these conditions to specific treatments whether it be erectile dysfunction, hair loss, dermatology, weight loss, whatever it is, we have a large number of patients coming through the door every single day. Initially, my thinking was, our thinking was, what can we do to impact positively the long-term health of these patients in a more profound way rather than treating them for this initial condition? When we kind of combine that thinking with the fact that most Americans are on high-deductible health plans, where it's oftentimes expensive for them to access prescription medications or even to go see a primary care physician, we believe that many of these patients that are already on our platform for condition-specific treatment would love to pay $50 or $100 a month, some of them more, to have in essence a doctor in the family to pick up the phone when something's wrong and they want to talk to the doctor to be able to get a prescription refilled. In addition to providing that ongoing care for these patients, for a small monthly cash fee that everybody can afford, we can also provide these patients heavily discounted generic drugs, we can provide them with discounted labs, and we can offer them discounts on a lot of these different more lifestyle treatments that are cash pay things like EB, things like weight loss. So the net amount that the patient is actually paying to have this incredible concierge service with a long-term relationship with the same doctor, we look at as being affordable to every American needs to be presented in the right way. It's going to be very popular. As far as David, thinking about the brick and mortar or referral relationships, it's a specialist. We think that as we scale this platform and start to put patients on the platform, we think that there are going to be a lot of opportunities for us to partner with regional, kind of brick and mortar networks, right, that obviously are going to want to treat those patients. So initially, we haven't lined that up, we've spoken with some different groups that have expressed interest. As we scale, we have no interest in building that out. We believe that we know that we can treat most of the things that these patients need to see a doctor for in a virtual setting. And so the plan is to refer patients to partners when they need to go see a doctor in person. Does that help or anything that I missed?

Nope, that's actually very helpful. I have yet to meet an acute care hospital system that would decline incoming referrals from a virtual primary care practice. So makes sense to me, thanks very much. I’ll hop back in the queue.

Yes, and one thing I mentioned, David, that I forgot to emphasize, we're building a great technology platform that is similar to the kind of one medical but the world that would integrate in one place, all the patients' lab, almost their kind of medical history with us, pulling in all their medical records when they initially onboard onto the platform. We're really excited to launch that; we're aiming to launch in the summer. And also something to think about right, it also really encourages or enables us to offer other condition-specific treatments to patients within our system. So, for instance, once you come into LifeMD as a patient, you'll obviously be able to access treatment from Shapiro for hair loss or anything in the family of LifeMD brand. So, we think it'll really pull everything that we're doing nicely together and then be a great way for us to develop a longer-term relationship with our patients.

Next, we'll go to Andrew D'Silva from B. Riley Securities. Your line is open.

I just thought, I have a couple quick bookkeeping ones. As it relates to share count, is there a reason your 2020 share count of a full year's worth is higher than your fourth quarter 2020 share count?

I'm not sure about that, Andy, I'd have to check and get back to you. I mean, it sounds like it was an error.

Okay, I wasn't sure if there was some sort of action or buyback or something I missed, but okay, that's fine. And then could you just discuss buys as you enter 2021 and what kind of benefits you’re seeing post-Election? And I'd also just be curious if you could let us know how we should think about modeling overhead tied to the call center?

Sure. Overall, we've seen the fourth quarter or third, fourth quarter especially, before the election, coming to the holidays was a very expensive time for the media. Our media costs were at least double, a lot of the time from what they were earlier in the year, and they've come down considerably in 2021. Also, we've seen a lot. We've realized a lot of operational efficiencies. We've done a lot of other optimization areas where we've been able to optimize our advertising and our checkout processes and other systems that helped us to put downward pressure on our overall acquisition costs. So I don't know the exact number Andy, but our acquisition costs more scale this quarter are significantly lower than they were in the fourth quarter of last year. Marc, I don't know if you could provide any additional color on that?

In general, what we're seeing strong returns on the advertising spend, were significantly lower as Justin mentioned in quarter one. What we're typically seeing is from the cohorts that we've had that have been in existence for 12 months or more, we’re paying back on the advertising investment within the first three to four months, and we're more than doubling our money within the first 12 months. So those are strong returns, and as you carry that forward and we continue to get more and more tenure with those subscribers, I would also remind you this was pre-off transitioning a lot of folks to the subscription model, we expect to see very substantial long-term returns.

Okay, that makes sense. And can you make some color on the call center?

Yes, I mean the call center, without really saying exact statistic, we are receiving a strong return on investment. We're seeing good uptick for competitive reasons; we don't necessarily share exact specifics, but what I would say is ever since the first launch that we got up and running, we're seeing a strong return on investment each month. As far as growth in the call center goes, it has about a 250-seat capacity, and then we're going to grow our capabilities there as long as it makes sense, but it's also going to produce incremental revenue. So it would be more than a loss from a financial modeling standpoint.

Okay.

I think an important thing to point out is, if we look at where CPAs are now, even as we're scaling, we see a massive, massive opportunity even in the ED market right to continue to really grow our business throughout this year and probably beyond. Something they make projections two or three years out, but I really want to emphasize to everybody on the call that, I mean CPAs are, there's a lot of opportunity here even in these initial markets. Especially in erectile dysfunction, we're continuing to tighten the business, we brought in a lot of talent both on the marketing side and on their patient service side, and we're really encouraged by what's happening in that business and even what we're going to see growth wise over the next couple of quarters, like I can't emphasize that enough.

Okay, that makes sense, and I heard you just referenced acquisition cost being recouped in about three to four months and doubling over a five-year timeframe. So we look at sales and marketing expense for example in the fourth quarter, is that kind of the base that you're taking that off of, or is it more segmented or nuanced as far as the proportion of that sales and marketing that you're attributing to consumer acquisition costs that would be recouped in that kind of timeframe?

Yes, it's taken off of that metric. At the end of the day, the sales and marketing expense that we're spending is obviously driven by that acquisition, and I'd actually expect the return on investment that we spoke about the potential to increase over time. Predominantly due to the fact that we're launching, we’re obviously converting mostly to subscription revenue, which was something that wasn't present last year. Then secondly, as we start to look at LifeMD rolling out this concierge model, and we have greater ability to sell brand, to upsell and to retain people through a combo service product offering, we should actually see that return on investment improving more in the future on those advertising dollars going further.

Okay, great. And just last question for me as it relates to PDFSimpli. Could you discuss the cadence there? That segment actually seems to be growing faster than we were at modeling. I’m just curious how much of say the first quarter's $17 million expectation we should kind of earmark for PDFSimpli?

It’s very consistent with what you're saying in the fourth quarter. At the end of the day, it is continuing to grow by very high double-digits, very low triple digits. Suffice it to say it's lower than the growth rate of the significant triple digits that we're seeing in telehealth. But we can think about it relatively similarly, how you would think about the fourth quarter, maybe very similarly.

And at this time, this concludes our question-and-answer session. I'd now like to turn the call back over to Mr. Schreiber. Please go ahead.

Thanks, everyone for joining us on our call today and all the great questions. I'd like to give special thanks to our new shareholders who have recently invested in us and the new analysts who begun to follow LifeMD. We very much appreciate your support and participation in our amazing journey. Many more exciting things to come, that's for sure, which we look forward to reporting on our Q1 call, which is coming up soon. Meanwhile, be well and stay healthy. Christy, let's go ahead and wrap-up the call.

Thank you. Before we conclude today's call, I would like to provide the company's safe harbor statements that include important questions regarding forward-looking statements made during today's call. The information that the company has provided in this conference call includes forward-looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934. As amended regarding, among other things, the company's plans, strategies, and prospects both business and financial. While the company believes that its plans, intentions, and expectations that reflected in or suggested by these forward-looking statements are reasonable, the company cannot assure you that it will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Many of the forward-looking statements made during this conference call may be identified by the use of forward-looking words such as believe, expect, anticipate, should, planned, will, may, intend, estimated, and potential among others. Important factors that could cause actual results to differ materially from the forward-looking statements made during this conference call include market conditions and those set forth in reports or documents that the company files from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to LifeMD Incorporated or a person acting on its behalf are expressly qualified in their entirety by this cautionary language. Before we end today's conference call, I would like to remind everyone that this call will be available for replay starting later this evening. Please refer to today's earnings release for dial-in replay instructions available via the company's website at www.lifemd.com. Thank you for joining us today and this concludes the conference call. You may now disconnect.